Our Capabilities-en

Our Capabilities-en (3)

The US Food and Drug Administration (FDA) on Wednesday released draft guidance to help sponsors establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended new measures to avoid dosing errors that have led to some patients incorrectly taking methotrexate-containing medicines daily instead of weekly.

The abuse of New Psychoactive Substances (NPS) has emerged in an endless stream, affecting the physical and mental health of the people and the overall competitiveness of the country. According to the United Nations Office on Drugs and Crime (UNODC), there has been an accumulated 943 NPS reported as of April 2019. The Food and Drug Administration, Ministry of Health and Welfare (TFDA) organizes the “2019 International Conference on New Psychoactive Substances” on 10-11 July.